

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2011/119663 A8

(43) International Publication Date
29 September 2011 (29.09.2011)

- (51) International Patent Classification:
A01N 43/38 (2006.01) *A61K 31/405* (2006.01)
- (21) International Application Number:
PCT/US2011/029511
- (22) International Filing Date:
23 March 2011 (23.03.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/317,476 25 March 2010 (25.03.2010) US
61/352,863 9 June 2010 (09.06.2010) US
61/381,480 10 September 2010 (10.09.2010) US
61/388,151 30 September 2010 (30.09.2010) US
61/419,068 2 December 2010 (02.12.2010) US
- (71) Applicant (for all designated States except US): **GLAXO-SMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **AXTEN, Jeffrey, Michael** [US/US]; 1250 South Collegeville Road, Col-


legeville, PA 19426 (US). **GRANT, Seth, Wilson** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **HEERDING, Dirk, A.** [NL/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **MEDINA, Jesus, Raul** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **ROMERIL, Stuart, Paul** [GB/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **TANG, Jun** [CN/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agents: **DERMOTT, Jonathan, M.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King Of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,

[Continued on next page]

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I wherein R¹, R² and R³ are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.



SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

26 October 2012

(15) Information about Correction:

see Notice of 26 October 2012

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))